{
    "clinical_study": {
        "@rank": "67171", 
        "arm_group": [
            {
                "arm_group_label": "pretreatment group", 
                "arm_group_type": "No Intervention", 
                "description": "doppler evaluation at pretreatment period"
            }, 
            {
                "arm_group_label": "posttreatment group", 
                "arm_group_type": "Experimental", 
                "description": "doppler evaluat\u0131on in normoprolactinemia women who given cabergoline treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "the investigators examined the hypothesis that hyperprolactinemia may alter uterin,\n      endometrial and intraovarian blood flow and may contribute to increased infertility by\n      another way."
        }, 
        "brief_title": "Color Doppler Analys\u0131s Of Uterin And Intraovarian Blood Flow Before And After Treatment W\u0131th Cabergoline In Hyperprolactinemic Patients", 
        "completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "condition": "Adverse Reaction to Other Drugs and Medicines", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women who had blood prolactin level higher than 25ng/dl\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Use of drugs effecting vasculature such as hormonal therapy, oral contraceptives,\n             antihypertensives\n\n          -  Diseases like pelvic inflammatory disease and systemic  hypertension\n\n          -  Women with clinically overt or treated cardiovascular disease\n\n          -  Concurrent illness other than hyperprolactinemia"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957839", 
            "org_study_id": "A\u015f\u0131c\u0131o\u011flu-08", 
            "secondary_id": "OA8"
        }, 
        "intervention": {
            "arm_group_label": "posttreatment group", 
            "description": "cabergoline treatment for hyperprolactinemia group", 
            "intervention_name": "cabergoline treatment", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cabergoline"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sisli", 
                    "country": "Turkey"
                }, 
                "name": "Sisli Etfal Teaching Hosital"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "S\u0130SL\u0130 ETFAL TEACH\u0130NG HOSP\u0130TAL", 
            "last_name": "Osman Temizkan, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "turkey:turkey healty ministry", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "th effect of prolactin vascular flow and resistance", 
            "safety_issue": "Yes", 
            "time_frame": "the effect of prolactin in vascular resistance at 2 weeks after treatment"
        }, 
        "reference": {
            "PMID": "20357175", 
            "citation": "Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab. 2010 Jun;95(6):2672-9. doi: 10.1210/jc.2009-2605. Epub 2010 Mar 31."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957839"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Istanbul Bakirkoy Maternity and Children Diseases Hospital", 
            "investigator_full_name": "Osman A\u015f\u0131c\u0131o\u011flu", 
            "investigator_title": "sisli etfal teaching hospital department gynecology and obstetric", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Istanbul Bakirkoy Maternity and Children Diseases Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Istanbul Bakirkoy Maternity and Children Diseases Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}